A candidate gene therapy for haemophilia B developed by scientists at University College London (UCL) was so effective in a Phase 1/2 study that Syncona LLP has decided to start a new company to commercialise it. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Regenerative Medicine Clinical Research
